AI, prevention and policy alignment take focus at WHX in Dubai
As WHX gets underway, discussions in Dubai will highlight how healthcare policy, technology deployment, and financing models are increasingly aligned in the UAE
09 February, 2026
TT
16
The World Health Expo (WHX) in Dubai opened on February 9, as the UAE steps up its efforts to integrate artificial intelligence, prevention, and digital infrastructure into its national healthcare systems.
Running until February 12 at the Dubai Exhibition Centre in Expo City Dubai, WHX, formerly known as Arab Health, comes as the UAE accelerates its healthcare reform to support population health, long-term system resilience, and cost sustainability.
Organisers expect more than 235,000 professional visits and 4,300 exhibitors from over 180 countries. When combined with WHX Labs, formerly Medlab Middle East, total visits are expected to exceed 270,000, reinforcing Dubai’s role as a regional hub for healthcare policy, technology, and investment discussions.
Beyond scale, the agenda reflects a shift in focus toward deployment and system readiness, as UAE healthcare stakeholders move AI and digital health from pilots into national planning.
Preventive, AI-enabled healthcare at the core
The Department of Health – Abu Dhabi (DoH) is using WHX 2026 to outline how AI and data are being embedded into preventative healthcare models. Presenting under the “Emirates Health” platform, DoH is showcasing initiatives designed to support early intervention, population health intelligence, and emergency preparedness.
Nine initiatives are on display, spanning genomics, disease prevention, and digital infrastructure. These include premarital genetic testing, newborn screening, pharmacogenomics programmes, AI-driven population health tools, and platforms such as the Unified Medical Operations Command Centre VR and the Indoor Air Quality Observatory.
Dr Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, said the emirate is focused on building an intelligent health system that anticipates risk and improves long-term outcomes, supported by strong regulatory frameworks and international collaboration.
Abu Dhabi’s approach reflects a broader UAE trend, where regulators are taking an active role in shaping digital health ecosystems rather than limiting their role to oversight.
Private sector players at WHX are aligning innovation with national healthcare objectives. Siemens Healthineers Middle East and Africa is presenting AI-enabled imaging, diagnostics, and digital solutions aimed at improving clinical outcomes and operational efficiency across UAE healthcare facilities.
Vivek Kanade, MD for Siemens Healthineers Middle East and Africa, said the focus is on oncology, cardiology, neurology, and neurodegenerative diseases, alongside digital tools that support hospital planning, predictive simulations, and AI-assisted reporting.
He said the emphasis is on scalable deployment that integrates with existing healthcare workflows, supporting long-term system performance.
Chronic disease management moves up the policy agenda
Chronic disease remains a growing priority for the UAE’s healthcare system. Lilly META is highlighting obesity as a chronic condition that continues to be underdiagnosed and undertreated despite affecting more than one billion people globally.
Amr Saeed, head of the Cardiometabolic Business Unit at Lilly META, said obesity is linked to more than 200 complications, including diabetes and cardiovascular disease, yet often lacks structured diagnosis, insurance coverage, and long-term care pathways.
He pointed to the UAE’s Personalized Weight Management Programme as an example of policy-led intervention. The programme combines digital monitoring, clinician-led care, and reimbursement mechanisms to support sustained weight management and reduce long-term healthcare burden.
Lilly said its focus aligns with a broader UAE push toward evidence-based, digitally enabled chronic care, supported by sustained research investment. The company invested nearly $11bn in R&D in 2024, representing more than 24 per cent of annual sales.
Insurers adapt to preventive healthcare models
Insurance providers are also adjusting their role within the UAE healthcare ecosystem. Khulood Hafez, CEO of Technical Insurance Services (TIS), said insurers are increasingly adopting data-driven models that prioritise prevention and early intervention.
She noted that SMEs, which account for more than 90 per cent of UAE businesses, face rising healthcare costs and limited administrative capacity. Flexible benefit structures, combined with digital tools such as teleconsultations and predictive analytics, can help improve health outcomes while managing costs.
Hafez said insurers play a key role in supporting national priorities around chronic disease prevention and workforce wellbeing.
Global healthcare partners emphasise long-term innovation
Ousama Alhaj, GM and head of Human Pharma, Near East and UAE – Boehringer Ingelheim, said: “The UAE’s rise as a global destination for world-class healthcare is rooted in a long-term commitment to science, innovation, and partnerships that are designed to address real, unmet health needs. What distinguishes the country in the global healthcare landscape is not just the scale of investment, but the clarity of intent. There is a very deliberate focus on building a future-ready healthcare system that is science-led, innovation-driven, and centred on addressing real unmet patient needs. At Boehringer Ingelheim, research and innovation are at the core of everything we do, with a clear focus on diseases where patients continue to face limited treatment options. As a purpose-driven, research-led biopharmaceutical company, we make sustained investments in research and development to advance breakthrough science across areas such as stroke, cardio-renal-metabolic disease, inflammatory conditions, and respiratory diseases.
“Across the region and Gulf, we see ourselves not only as a provider of innovative medicines, but as a long-term science and innovation partner contributing to the broader life sciences ecosystem. Our strategic collaboration with the Department of Health – Abu Dhabi and other emirates reflects a shared ambition to strengthen pharmaceutical research, enable access to advanced scientific platforms, and empower the local research community. Through initiatives such as open research platforms and global scientific collaboration models, we support knowledge exchange, accelerate discovery, and help bridge the gap between early-stage research and real-world impact.
As WHX 2026 gets underway, discussions in Dubai highlight how healthcare policy, technology deployment, and financing models are increasingly aligned in the UAE.
AI, digital platforms, and preventive care are moving from pilot programmes into system-level implementation, supported by regulatory coordination and public-private collaboration.
The event underscores how the UAE is shaping healthcare reform around long-term infrastructure, data integration, and population health outcomes.




















